Skip to main content
Top
Published in: Health and Quality of Life Outcomes 1/2020

Open Access 01-12-2020 | Research

Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer

Authors: Yasuhiro Hagiwara, Takeru Shiroiwa, Naruto Taira, Takuya Kawahara, Keiko Konomura, Shinichi Noto, Takashi Fukuda, Kojiro Shimozuma

Published in: Health and Quality of Life Outcomes | Issue 1/2020

Login to get access

Abstract

Background

To develop direct and indirect (response) mapping algorithms from the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire Core 30 (EORTC QLQ-C30) and the Functional Assessment of Cancer Therapy General (FACT-G) onto the EQ-5D-5L index.

Methods

We conducted the QOL-MAC study where EQ-5D-5L, EORTC QLQ-C30, and FACT-G were cross-sectionally evaluated in patients receiving drug treatment for solid tumors in Japan. We developed direct and indirect mapping algorithms using 7 regression methods. Direct mapping was based on the Japanese value set. We evaluated the predictive performances based on root mean squared error (RMSE), mean absolute error, and correlation between the observed and predicted EQ-5D-5L indexes.

Results

Based on data from 903 and 908 patients for EORTC QLQ-C30 and FACT-G, respectively, we recommend two-part beta regression for direct mapping and ordinal logistic regression for indirect mapping for both EORTC QLQ-C30 and FACT-G. Cross-validated RMSE were 0.101 in the two methods for EORTC QLQ-C30, whereas they were 0.121 in two-part beta regression and 0.120 in ordinal logistic regression for FACT-G. The mean EQ-5D-5L index and cumulative distribution function simulated from the recommended mapping algorithms generally matched with the observed ones except for very good health (both source measures) and poor health (only FACT-G).

Conclusions

The developed mapping algorithms can be used to generate the EQ-5D-5L index from EORTC QLQ-C30 or FACT-G in cost-effectiveness analyses, whose predictive performance would be similar to or better than those of previous algorithms.
Appendix
Available only for authorised users
Literature
1.
go back to reference Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef Bray F, Ferlay J, Soerjomataram I, Siegel RL, Torre LA, Jemal A. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68:394–424.CrossRef
2.
go back to reference Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019;7:1–6.CrossRef Yu PP, Eton O, Garrison LP. Challenges in assessing the clinical utility and economic value of immune checkpoint inhibitor therapies of Cancer. J Immunother Cancer. 2019;7:1–6.CrossRef
3.
go back to reference Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:1–15.CrossRef Verma V, Sprave T, Haque W, Simone CB, Chang JY, Welsh JW, et al. A systematic review of the cost and cost-effectiveness studies of immune checkpoint inhibitors. J Immunother Cancer. 2018;6:1–15.CrossRef
4.
go back to reference Weinstein M, Torrance G, Mcguire A. QALYs: The Basics. Value Health. 2009;12:S5-9. Weinstein M, Torrance G, Mcguire A. QALYs: The Basics. Value Health. 2009;12:S5-9.
5.
go back to reference Brooks R, De Charro F. EuroQol: the current state of play. Health Policy. 1996;37:53–72.CrossRef Brooks R, De Charro F. EuroQol: the current state of play. Health Policy. 1996;37:53–72.CrossRef
7.
go back to reference Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2019;23:43–51.CrossRef Hasegawa M, Komoto S, Shiroiwa T, Fukuda T. Formal implementation of cost-effectiveness evaluations in Japan: a unique health technology assessment system. Value Health. 2019;23:43–51.CrossRef
9.
go back to reference Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36:675–97.CrossRef Janssen MF, Bonsel GJ, Luo N. Is EQ-5D-5L better than EQ-5D-3L? A head-to-head comparison of descriptive systems and value sets from seven countries. Pharmacoeconomics. 2018;36:675–97.CrossRef
10.
go back to reference Selivanova A, Buskens E, Krabbe PFM. Head-to-head comparison of EQ-5D-3L and EQ-5D-5L health values. Pharmacoeconomics. 2018;36:715–25.CrossRef Selivanova A, Buskens E, Krabbe PFM. Head-to-head comparison of EQ-5D-3L and EQ-5D-5L health values. Pharmacoeconomics. 2018;36:715–25.CrossRef
11.
go back to reference Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRef Herdman M, Gudex C, Lloyd A, Janssen M, Kind P, Parkin D, et al. Development and preliminary testing of the new five-level version of EQ-5D (EQ-5D-5L). Qual Life Res. 2011;20:1727–36.CrossRef
12.
go back to reference Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993;85:365–76.CrossRef
13.
go back to reference Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.CrossRef Cella DF, Tulsky DS, Gray G, Sarafian B, Linn E, Bonomi A, et al. The functional assessment of cancer therapy scale: development and validation of the general measure. J Clin Oncol. 1993;11:570–9.CrossRef
14.
go back to reference Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Qual Life Res. 2016;25:891–911.CrossRef Doble B, Lorgelly P. Mapping the EORTC QLQ-C30 onto the EQ-5D-3L: assessing the external validity of existing mapping algorithms. Qual Life Res. 2016;25:891–911.CrossRef
15.
go back to reference Teckle P, McTaggart-Cowan H, Van der Hoek K, Chia S, Melosky B, Gelmon K, et al. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health Qual Life Outcomes. 2013;11:1–10.CrossRef Teckle P, McTaggart-Cowan H, Van der Hoek K, Chia S, Melosky B, Gelmon K, et al. Mapping the FACT-G cancer-specific quality of life instrument to the EQ-5D and SF-6D. Health Qual Life Outcomes. 2013;11:1–10.CrossRef
16.
go back to reference Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Making. 2015;35:912–26.CrossRef Young TA, Mukuria C, Rowen D, Brazier JE, Longworth L. Mapping functions in health-related quality of life: mapping from two cancer-specific health-related quality-of-life instruments to EQ-5D-3L. Med Decis Making. 2015;35:912–26.CrossRef
17.
go back to reference Khan I, Morris S, Pashayan N, Matata B, Bashir Z, Maguirre J. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016;14:1–15.CrossRef Khan I, Morris S, Pashayan N, Matata B, Bashir Z, Maguirre J. Comparing the mapping between EQ-5D-5L, EQ-5D-3L and the EORTC-QLQ-C30 in non-small cell lung cancer patients. Health Qual Life Outcomes. 2016;14:1–15.CrossRef
18.
go back to reference Lamu AN, Olsen JA. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D. Qual Life Res. 2018;27:2823–39.CrossRef Lamu AN, Olsen JA. Testing alternative regression models to predict utilities: mapping the QLQ-C30 onto the EQ-5D-5L and the SF-6D. Qual Life Res. 2018;27:2823–39.CrossRef
19.
go back to reference Ameri H, Yousefi M, Yaseri M, Nahvijou A, Arab M, Sari AA. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2019;19:89–96.CrossRef Ameri H, Yousefi M, Yaseri M, Nahvijou A, Arab M, Sari AA. Mapping the cancer-specific QLQ-C30 onto the generic EQ-5D-5L and SF-6D in colorectal cancer patients. Expert Rev Pharmacoecon Outcomes Res. 2019;19:89–96.CrossRef
20.
go back to reference Ameri H, Yousefi M, Yaseri M, Nahvijou A, Arab M, Sari AA. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in colorectal cancer patients. J Gastrointest Cancer. 2020;51:196–203.CrossRef Ameri H, Yousefi M, Yaseri M, Nahvijou A, Arab M, Sari AA. Mapping EORTC-QLQ-C30 and QLQ-CR29 onto EQ-5D-5L in colorectal cancer patients. J Gastrointest Cancer. 2020;51:196–203.CrossRef
21.
go back to reference Meregaglia M, Borsoi L, Cairns J, Tarricone R. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. Eur J Heal Econ. 2019;20:181–93.CrossRef Meregaglia M, Borsoi L, Cairns J, Tarricone R. Mapping health-related quality of life scores from FACT-G, FAACT, and FACIT-F onto preference-based EQ-5D-5L utilities in non-small cell lung cancer cachexia. Eur J Heal Econ. 2019;20:181–93.CrossRef
22.
go back to reference Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: An online database and application of the MAPS statement. Health Qual Life Outcomes. Health and Quality of Life Outcomes; 2018;16:1–9. Dakin H, Abel L, Burns R, Yang Y. Review and critical appraisal of studies mapping from quality of life or clinical measures to EQ-5D: An online database and application of the MAPS statement. Health Qual Life Outcomes. Health and Quality of Life Outcomes; 2018;16:1–9.
23.
go back to reference Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, et al. Comparison of value set based on DCE and/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health. 2016;19:648–54.CrossRef Shiroiwa T, Ikeda S, Noto S, Igarashi A, Fukuda T, Saito S, et al. Comparison of value set based on DCE and/or TTO data: scoring for EQ-5D-5L health states in Japan. Value Health. 2016;19:648–54.CrossRef
24.
go back to reference Steyerberg EW. Clinical prediction models. 2nd ed. New York: Springer; 2019.CrossRef Steyerberg EW. Clinical prediction models. 2nd ed. New York: Springer; 2019.CrossRef
25.
go back to reference Khan I, Morris S. A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches. Health Qual Life Outcomes. 2014;12:1–16.CrossRef Khan I, Morris S. A non-linear beta-binomial regression model for mapping EORTC QLQ- C30 to the EQ-5D-3L in lung cancer patients: a comparison with existing approaches. Health Qual Life Outcomes. 2014;12:1–16.CrossRef
26.
go back to reference Dunn PK, Smyth GK. Series evaluation of Tweedie exponential dispersion model densities. Stat Comput. 2005;15:267–80.CrossRef Dunn PK, Smyth GK. Series evaluation of Tweedie exponential dispersion model densities. Stat Comput. 2005;15:267–80.CrossRef
27.
go back to reference Ospina R, Ferrari SLP. A general class of zero-or-one inflated beta regression models. Comput Stat Data Anal. 2012;56:1609–23.CrossRef Ospina R, Ferrari SLP. A general class of zero-or-one inflated beta regression models. Comput Stat Data Anal. 2012;56:1609–23.CrossRef
28.
go back to reference Hunger M, Döring A, Holle R. Longitudinal beta regression models for analyzing health-related quality of life scores over time. BMC Med Res Methodol. 2012;12:144.CrossRef Hunger M, Döring A, Holle R. Longitudinal beta regression models for analyzing health-related quality of life scores over time. BMC Med Res Methodol. 2012;12:144.CrossRef
29.
go back to reference Yang Q, Yu XX, Zhang W, Li H. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China. Health Qual Life Outcomes. 2019;17:1–12.CrossRef Yang Q, Yu XX, Zhang W, Li H. Mapping function from FACT-B to EQ-5D-5 L using multiple modelling approaches: data from breast cancer patients in China. Health Qual Life Outcomes. 2019;17:1–12.CrossRef
30.
go back to reference Hernández Alava M, Wailoo A, Wolfe F, Michaud K. A Comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making. 2014;34:919–30.CrossRef Hernández Alava M, Wailoo A, Wolfe F, Michaud K. A Comparison of direct and indirect methods for the estimation of health utilities from clinical outcomes. Med Decis Making. 2014;34:919–30.CrossRef
31.
go back to reference Wailoo A, Hernández M, Philips C, Brophy S, Siebert S. Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Health. 2015;18:425–31.CrossRef Wailoo A, Hernández M, Philips C, Brophy S, Siebert S. Modeling health state utility values in ankylosing spondylitis: comparisons of direct and indirect methods. Value Health. 2015;18:425–31.CrossRef
32.
go back to reference Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: Issues, evidence and recommendations. Ann Oncol. 2011;22:2179–90.CrossRef Luckett T, King MT, Butow PN, Oguchi M, Rankin N, Price MA, et al. Choosing between the EORTC QLQ-C30 and FACT-G for measuring health-related quality of life in cancer clinical research: Issues, evidence and recommendations. Ann Oncol. 2011;22:2179–90.CrossRef
33.
go back to reference Kemmler BG, Holzner B, Kopp M, Du M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932–40.CrossRef Kemmler BG, Holzner B, Kopp M, Du M, Margreiter R, Greil R, et al. Comparison of two quality-of-life instruments for cancer patients: the functional assessment of cancer therapy-general and the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-C30. J Clin Oncol. 1999;17:2932–40.CrossRef
34.
go back to reference Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20:18–27.CrossRef Wailoo AJ, Hernandez-Alava M, Manca A, Mejia A, Ray J, Crawford B, et al. Mapping to estimate health-state utility from non-preference-based outcome measures: an ISPOR good practices for outcomes research task force report. Value Health. 2017;20:18–27.CrossRef
35.
go back to reference Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15:550–61.CrossRef Hernández Alava M, Wailoo AJ, Ara R. Tails from the peak district: adjusted limited dependent variable mixture models of EQ-5D questionnaire health state utility values. Value Health. 2012;15:550–61.CrossRef
36.
go back to reference Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B instrument to EQ-5D-3L in patients with breast cancer using adjusted limited dependent variable mixture models versus response mapping. Value Health. 2018;21:1399–405.CrossRef Gray LA, Wailoo AJ, Hernandez AM. Mapping the FACT-B instrument to EQ-5D-3L in patients with breast cancer using adjusted limited dependent variable mixture models versus response mapping. Value Health. 2018;21:1399–405.CrossRef
Metadata
Title
Mapping EORTC QLQ-C30 and FACT-G onto EQ-5D-5L index for patients with cancer
Authors
Yasuhiro Hagiwara
Takeru Shiroiwa
Naruto Taira
Takuya Kawahara
Keiko Konomura
Shinichi Noto
Takashi Fukuda
Kojiro Shimozuma
Publication date
01-12-2020
Publisher
BioMed Central
Published in
Health and Quality of Life Outcomes / Issue 1/2020
Electronic ISSN: 1477-7525
DOI
https://doi.org/10.1186/s12955-020-01611-w

Other articles of this Issue 1/2020

Health and Quality of Life Outcomes 1/2020 Go to the issue